Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
64 results about "Prevention of diabetes mellitus type 2" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Prevention of diabetes mellitus type 2 can be achieved with both lifestyle changes and use of medication. The American Diabetes Association categorizes prediabetes as a high-risk group that has glycemic levels higher than normal but does not meet criteria for diabetes. Without intervention people with prediabetes progress to type 2 diabetes with a 5% to 10% rate. Diabetes prevention is achieved through weight loss and increased physical activity, which can reduce the risk of diabetes by 50% to 60%.
Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
InactiveUS6710040B1Easy to prepareEase of detectabilityBiocideOrganic chemistryAcute coronary syndromeDisease progression
The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, hyperglycemia, impaired glucose tolerance, metabolic syndrome (Syndrome X or insulin resistance syndrome), glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of identifying an insulin secretagogue agent for diabetes.
Owner:PFIZER INC
Synthesis of 3,3,4,4-tetrafluoropyrrolidine and novel dipeptidyl peptidase-IV inhibitor compounds
The present invention relates to a method of making novel dipeptidyl peptidase-IV ("DPP-IV') inhibitor compounds useful for treating, inter alia, diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, metabolic syndrome (Syndrome X or insulin resistance syndrome), hyperglycemia, impaired glucose tolerance, glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of making 3,3,4,4-tetrafluoropyrrolidine, a starting material utilized in the afore-mentioned method for preparing DPP-IV compounds.
Owner:PFIZER INC
Compositions and methods relating to glucagon receptor antibodies
ActiveUS7947809B2Lowering blood glucoseImprove glucose toleranceMetabolism disorderDigestive systemPrevention of diabetes mellitus type 2Antigen binding
The present disclosure provides compositions and methods relating to antigen binding proteins, in particular, antibodies which specifically bind to the human glucagon receptor. The disclosure provides nucleic acids encoding such antigen binding proteins and antibodies and methods of making and using such antibodies including methods of treating and preventing type 2 diabetes and related disorders by administering such antibodies to a subject in need of such treatment.
Owner:AMGEN INC
Compositions and methods relating to glucagon receptor antibodies
ActiveUS20090041784A1Lowering blood glucoseImprove glucose toleranceImmunoglobulins against cell receptors/antigens/surface-determinantsFermentationPrevention of diabetes mellitus type 2Antigen binding
The present disclosure provides compositions and methods relating to antigen binding proteins, in particular, antibodies which specifically bind to the human glucagon receptor. The disclosure provides nucleic acids encoding such antigen binding proteins and antibodies and methods of making and using such antibodies including methods of treating and preventing type 2 diabetes and related disorders by administering such antibodies to a subject in need of such treatment.
Owner:AMGEN INC
Synthesis of 3,3,4,4-tetrafluoropyrrolidine and novel dipeptidyl peptidase-IV inhibitor compounds
InactiveUS6812350B2Metabolism disorderPhosphorus organic compoundsDisease progressionDiabetic nephropathy
Owner:PFIZER INC
Synthesis of 3,3,4,4-tetrafluoropyrrolidine and novel dipeptidyl peptidase-IV inhibitor compounds
InactiveUS20040002609A1Easy to cutMetabolism disorderPhosphorus organic compoundsDisease progressionDisease cause
The present invention relates to a method of making novel dipeptidyl peptidase-IV ("DPP-IV') inhibitor compounds useful for treating, inter alia, diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, metabolic syndrome (Syndrome X or insulin resistance syndrome), hyperglycemia, impaired glucose tolerance, glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of making 3,3,4,4-tetrafluoropyrrolidine, a starting material utilized in the afore-mentioned method for preparing DPP-IV compounds.
Owner:PFIZER INC
Phenolic antioxidant-chromium complexes for treatment or prevention of type 2 diabetes or glucose intolerance
InactiveUS20050085454A1Reducing hyperglycemiaStabilize blood sugar levelsBiocideHeavy metal active ingredientsMedicinePhenolic antioxidant
A composition for the treatment, prevention or management of a condition in primates, especially humans comprising a phenolic antioxidant-chromium complex.
Owner:INDIAN HERBS RES & SUPPLY +1
Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
InactiveUS20040132713A1Ease of preparation and detectabilityGood metabolic stabilityBiocideOrganic chemistryDisease progressionDiabetic nephropathy
The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, hyperglycemia, impaired glucose tolerance, metabolic syndrome (Syndrome X or insulin resistance syndrome), glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of identifying an insulin secretagogue agent for diabetes.
Owner:PFIZER INC
Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
Owner:MERCK SHARP & DOHME LLC
Glucagon-Like Peptide-1 derivatives and their pharmaceutical use
The invention relates to protracted Glucagon-Like Peptide-1 (GLP-1) derivatives and therapeutic uses thereof. The GLP-1 derivative of the invention comprises a modified GLP-1(7-37) sequence having a total of 2-12 amino acid modifications, including Glu22 and Arg26, and being derivatised with an albumin binding residue or pegylated in position 18, 20, 23, 30, 31, 34, 36, 37, or 39. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, stable, have long half-lives, a high affinity of binding to albumin, and / or a high affinity of binding to the extracellular domain of the GLP-1 receptor (GLP-1R), all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration.
Owner:NOVO NORDISK AS
Peptides Derivatized with A-B-C-D- and their Therapeutical Use
The invention relates to protracted peptide derivatives such as Glucagon-Like Peptide-1 (GLP-1), exendin-4, and analogues thereof, as well as therapeutic uses thereof. The peptide derivative of the invention comprises a peptide wherein at least one amino acid residue is derivatized with A-B—C—, or A-B—C-D-. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, have a low ratio of binding affinity to the GLP-1 receptor in the presence of high / low albumin concentrations, have long half-lives, and have a high affinity of binding to albumin, all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration.
Owner:NOVO NORDISK AS
Lactobacillus rhamnosus CCFM0528 having diabetes preventing effect
ActiveCN103275905ALower fasting blood sugar levelsImprove toleranceMilk preparationBacteriaLactobacillus rhamnosusAlpha-glucosidase activity
Owner:JIANGNAN UNIV
Glucagon-like peptide-1 derivatives and their pharmaceutical use
The invention relates to protracted Glucagon-Like Peptide-1 (GLP-1) derivatives and therapeutic uses thereof. The GLP-1 derivative of the invention comprises a modified GLP-1(7-37) sequence having a total of 2-12 amino acid modifications, including Glu22 and Arg26, and being derivatised with an albumin binding residue or pegylated in position 18, 20, 23, 30, 31, 34, 36, 37, or 39. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, stable, have long half-lives, a high affinity of binding to albumin, and / or a high affinity of binding to the extracellular domain of the GLP-1 receptor (GLP-1R), all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration.
Owner:NOVO NORDISK AS
Methods for the treatment of IL-1β related diseases
ActiveUS7695718B2Lower Level RequirementsReduce decreaseBiocideSenses disorderAcute hyperglycaemiaDisease
Owner:XOMA (US) LLC
A kind of cinnamon polyphenol extract, its preparation method and use
InactiveCN102274244ALower blood sugarIncreased sensitivityAnthropod material medical ingredientsMetabolism disorderLiver functionCinnamomum
The invention relates to the field of natural medicaments, in particular to a cassia bark polyphenol extract and a preparation method and application thereof. The preparation method is characterized by comprising the following steps of: removing fat soluble substances from cassia bark by using CO2 supercritical extraction, extracting extraction residues by water or a water mixed solvent to obtaina cassia bark polyphenol coarse extract of which the content of total phenol is about 6 percent, and purifying by using SP207 macroporous adsorbent resin to obtain the cassia bark polyphenol extract,wherein the content of total polyphenol is over 26 percent, the purity is high, and the quality is stable. In the cassia bark polyphenol extract, cassia bark polyphenol has the effects of reducing blood sugar, regulating blood fat and improving liver functions in the treatment and prevention of type 2 diabetes.
Owner:CHINA PHARM UNIV +1
Peptides derivatized with a-b-c-d- and their therapeutical use
The invention relates to protracted peptide derivatives such as Glucagon-Like Peptide-1 (GLP-1), exendin-4, and analogues thereof, as well as therapeutic uses thereof. The peptide derivative of the invention comprises a peptide wherein at least one amino acid residue is derivatized with A-B-C-, or A-B-C-D-. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, have a low ratio of binding affinity to the GLP-1 receptor in the presence of high / low albumin concentrations, have long half-lives, and have a high affinity of binding to albumin, all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration.
Owner:NOVO NORDISK AS
Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity
ActiveUS7268157B2Decrease hyperglycemiaDecrease hypertriglyceremiaBiocideOrganic chemistryAcute hyperglycaemiaCoronary artery disease
Disclosed is the preparation and pharmaceutical use of substituted arylalcanoic acid derivatives of Formula I, wherein ring A, ring B, R1, R2, R3, R4, R5, X, Alk1, Alk2, Ar1, and Ar2 are as defined in the specification. These compounds, as selective agonists activating peroxisome proliferator-activated receptors (PPAR), in particularly the RXR / PPARalpha, RXR / PPARgamma, and RXR / PPARdelta heterodimers, are useful in the treatment and / or prevention of type 2 diabetes and associated metabolic syndrome such as hypertension, obesity, insulin resistance, hyperlipidemia, hyperglycemia, hypercholesterolemia, atherosclerosis, coronary artery disease, and other cardiovascular disorders with improved side effects profile commonly associated with conventional PPARgamma agonists.
Owner:SHENZHEN CHIPSCREEN BIOSCIENCES CO LTD
Methods for the treatment of il-1beta related diseases
ActiveUS20080292640A1Reduce the amount requiredReduce frequencyBiocideSenses disorderAcute hyperglycaemiaHyperinsulinemia
Disclosed are methods for the treatment and / or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, obesity, hyperglycemia, hyperinsulinemia and Type 1 diabetes, comprising administering to a subject an effective amount of anti-IL-1β antibody or fragment thereof.
Owner:XOMA US
Rhizoma anemarrhenae extrac and applications as type 2 diabetes-curing medicine thereof
InactiveCN101229316AIncrease the number of receptorsReduce resistanceMetabolism disorderPlant ingredientsSeparation technologyKetone
The invention discloses an anemarrhenae extract and the application as a medicine treating type II diabetes thereof. The invention uses membrane separation technology, macropore to absorb resin separation and refines anemarrhenae extract after extracting the hizome anemarrhenae by water and ethanol with water. The main activities of the anemarrhenae extract of the invention are three kinds or any two kinds among anemarrhenae saponins, anemarrhenae polysaccharides and double benzene pyrrole ketones, and the total content of the main active components is up to more than 50 percent. The pharmacological experiment of the anemarrhenae extract of the invention proves that the medicine has a big medical value and economic benefit as the medicine for treating or preventing type II diabetes and the complications thereof.
Owner:GUANGDONG PHARMA UNIV
Acyl bipiperidinyl compounds, compositions containing such compounds and methods of treatment
Owner:MERCK SHARP & DOHME CORP
Use of an interleukin 1 receptor antagonist and/or pyrrolidinedithiocarbamate for the treatment or prophylaxis of type 2 diabetes
Owner:UNIV ZURICH
Antagonist anti-il-7 receptor antibodies and methods
The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (IL-7R). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof for the treatment and / or prevention of type 2 diabetes and immunological disorders, including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, graft-versus-host disease, and lupus.
Owner:RINAT NEUROSCI CORP
Application of ferric iron ferriporphyrin compound in preparation of anti-type-2 diabetes drug
ActiveCN102935222AHigh ascorbate peroxidase activityReduce cholesterolDipeptide ingredientsMetabolism disorderPeroxidaseSuperoxide
The invention provides application of a ferric iron ferriporphyrin compound in preparation of an anti-type-2 diabetes drug and belongs to the technical field of biological pharmacy. The ferric iron ferriporphyrin compound consists of heme and oligopeptide. A carboxyl of the heme is connected with an amino on a peptide chain through an amido bond to achieve connection of the heme and the oligopeptide. Other type-2 diabetes treating or preventing drugs can be applied to the drug preparation. The ferric iron ferriporphyrin compound serves as a peroxidase stimulant, has small molecular weight, can enter cells to effectively remove internal superoxide, super-oxygen ions and free radicals and has the effects of reducing blood sugar, cholesterol and triglycerides activity.
Owner:吉林省润宝生物科技有限公司
Compositions and methods for diabetes treatment
InactiveUS20120232003A1Easy to manageHigh indexBiocideDispersion deliveryMelatonin agonistPrevention of diabetes mellitus type 2
Owner:TAKAHASHI JOSEPH S +1
Treatment of diabetes and diabetic complications with NHE-1 inhibitors
This invention relates to methods of treating or preventing type 2 diabetes, diabetic neuropathy, diabetic cardiomyopathy, cataracts, diabetic retinopathy, foot ulcers, diabetic microangiopathy, diabetic macroangiopathy, diabetic ischemia reperfusion injury, diabetic cardiac ischemia reperfusion injury and / or insulin resistance syndrome (IRS) in mammals, particularly in humans, by administering a sodium-hydrogen exchanger type 1 (NHE-1) inhibitor or a pharmaceutical composition containing such an inhibitor. This invention also relates to combinations comprising NHE-1 inhibitors and a second pharmaceutical agent, said combinations being useful in treating type 2 diabetes, IRS, diabetic neuropathy, diabetic cardiomyopathy, cataracts, diabetic retinopathy, foot ulcers, diabetic ischemia reperfusion injury, diabetic cardiac ischemia reperfusion injury, diabetic microangiopathy and / or diabetic macroangiopathy.
Owner:PFIZER INC
Fuel reforming device
Substances that inhibit the action of the members of the IL-1β / NF-κB pathway can be used for protecting and preserving β-cell mass and function in prediabetic and diabetic type 2 patients. Specifically, the present invention relates to the use of an Interleukin 1 receptor antagonist (IL-1Ra) and / or pyrrolidinedithiocarbamate (PDTC) for the treatment or prophylaxis of type 2 diabetes, as well as a method for the treatment of type 2 diabetes.
Owner:UNIV ZURICH
Health food or prevention of type 2 diabetes and preparation method thereof
The invention discloses a health food for prevention of type 2 diabetes and a preparation method thereof, relates to the field of natural green food. The health food is mainly composed of a luffa seed powder, a food additive, and optionally a grain powder, a fruit juice or tea. The luffa powder is prepared by the following method: taking luffa seeds, washing the seeds, placing the seeds in an oven, baking for 12-18 h at 20-50 DEG C to obtain dried luffa seeds; hulling the luffa seeds, and grinding the seeds into a powder; and sieving the powder through a 100 mesh to obtain the luffa powder. The invention develops the health food with luffa seeds as the raw material for prevention of type 2 diabetes, and aims at glucose tolerant patients, the group with strong genetic background of type 2 diabetes, the group with irregular daily schedule and the obese.
Owner:GENSUN INST OF BIOMEDICINE
Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
Owner:MERCK SHARP & DOHME LLC
Method for treating and preventing type 2 diabetes
InactiveUS20130315925A1Less timeEfficient silencingOrganic active ingredientsSugar derivativesPrevention of diabetes mellitus type 2Acyltransferases
Methods and compositions for treating or preventing type 2 diabetes by inhibiting expression or activity of monoacylglycerol O-acyltransferase 1 (MOGAT1) are disclosed. Also disclosed are methods to identify such compositions.
Owner:BIOMEDCORE
Use of brown algae-derived glucuronic acid-rich low-sulfated heteroglycan in the preparation of medicaments for the treatment of type 2 diabetes
ActiveCN110218262AObvious effectOrganic active ingredientsMetabolism disorderUronic acidPrevention of diabetes mellitus type 2
The present invention provides the use of brown algae-derived glucuronic acid-rich low-sulfated heteroglycan in the preparation of medicaments or health products for the treatment and / or prevention oftype 2 diabetes. The low-sulfated heteroglycan has the following characteristics: the monosaccharide component mainly comprises fucose and glucuronic acid, and further comprises one or more of mannose, glucose, rhamnose, galactose, xylose, guluronic acid and mannuronic acid; wherein the content of the hydrolyzed sulfate group is 5 to 28 percent, the content of the fucose is 3 to 28 percent and the content of the uronic acid is 5 to 30 percent. The heteroglycan has stronger effect on promoting glucose consumption in HepG2 cells than fucoidan sulfate fraction, and it has obvious effect on enhancing insulin secretion in islet beta cells.
Owner:ZHEJIANG UNIV OF TECH
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com